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Abstract
Background and Objectives: Type 2 diabetes is becoming epidemic and several studies have shown that diabetes is 
associated with increased co-morbidities and impaired functional health in the general adult population. Type 2 diabetes 
is one of the co-morbidities associated with metabolic syndrome that carries with it increased risk of cardiovascular 
disease and death. The purpose of this study is therefore to determine the prevalence of metabolic syndrome in newly 
diagnosed type 2 diabetes mellitus subjects seen at Nnewi South East Nigeria.
Design and Setting: This is a cross-sectional study in newly diagnosed diabetics attending a private hospital-Hope 
Specialist Hospital, Nnewi.
Materials and Methods: One hundred and eighteen (118) newly diagnosed diabetic patients were recruited into the 
study consisting of those who on routine screening were found to have elevated blood glucose or were symptomatic 
of the disease and presented for treatment.
Statistical Analysis: Statistical analysis was carried out using SPSS version 13. Student’s t-test was used for continuous 
variables, and a χ2 test was used for categorical variables. In the analyses a P- value of <0.05 was considered statistically 
significant.
Results: Of the 118 subjects, 25 were removed from the study because their samples were lost as a result of prolonged 
power outage leaving 93 subjects consisting of 47 males and 46 females. The mean (SD) and the range of age was 
55.27 (12.55) years, 24-84 years; SBP 153.52 (29.83) mmHg,100-230 mmHg; DBP 94.23 (15.42) mmHg, 60-140 mmHg; 
TC 5.17 (1.4) mmol/L, 2.0-11.12 mmol/L; LDL-C 2.06 (1.55) mmol/L, 0.1-9.4 mmol/L; HDL-C 1.28 (0.48) mmol/L, 0.15-2.8 
mmol/L; TG 1.75 (0.85) mmol/L, 0.50-5.0 mmol/L; BMI 30.30 (6.23) kg/m2, 17.84-49.12 kg/m2; and WC of the general 
population mean (SD) 96.86 (7.16) cm, range 84-112 cm; for men 101.40 (3.88) cm, range 85-108 cm and for women 
92.22 (6.77) cm, 84-112 cm. Metabolic syndrome was found in 62 (66.7%) subjects of which 26 (41.9%) were males and 
36 (58.1%) were females (P < 0.019). The prevalence of different components of metabolic syndrome was as follows: 
hypertension was found in 75 (80.6%): 37 males and 38 females (P = 0.635), dyslipidemia in 31 (60.8%): 19 males and 
12 females (P = 0.572). Obesity was found in 23 (45.1%): 8 males and 15 females (P < 0.014). Of the study subjects 33 
had hypertension prior to the diagnosis of diabetes mellitus (DM). Seventeen males had hypertriglyceridemia against 
11 females (P = 0.357). Equal number of males and females (11 each) had low HDL--C (P = 0.603).
Conclusion: The study shows that metabolic syndrome is highly prevalent in newly diagnosed type 2 diabetes patients 
and the most common risk factor is hypertension.
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Introduction
Metabolic syndrome (MetS) is a widely prevalent and 
multi-factorial disorder. The syndrome has been given 
several names including the metabolic syndrome, the insulin 
resistance syndrome, the plurimetabolic syndrome, and 
the deadly quartet. Metabolic syndrome was first defined 
by Kylin, a Swedish Physician in 1923 as a clustering of 
hypertension, hyperglycemia, and gout.[1] It is estimated 
that around a quarter of the world’s adult population have 
MetS and they are twice as likely to die from and three times 
as likely to have a heart attack or stroke compared with 
people without the syndrome.[2] The United States Census 
Department has given an estimate of approximately 25% 
among its general population.[3]
With the formulation of the Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol 
in Adults (Adult Treatment Panel III) (NCEP-ATP III) 
guidelines, some uniformity and standardization occurred 
in the definition of the metabolic syndrome and this has 
been very useful for epidemiological purposes. Various 
criteria have been proposed by WHO,[4] NCEP-ATP III,[5] 
the European Group for the study of Insulin Resistance,[6] 
and the International Diabetes Federation (IDF).[7] There 
are essential components that are common to all definitions 
such as glucose intolerance, obesity, hypertension, and 
dyslipidemia though the exact criteria differ among 
definitions. Taken individually, each component of the 
MetS is a well- established risk factor for atherosclerotic 
cardiovascular disease (ASCVD). These factors act 
synergistically and increase the risk for ASCVD from two 
to three fold.[8] For subjects without diabetes the need for 
assessment of insulin resistance by either an oral glucose 
tolerance test or the hyperinsulinemic-euglycemic clamp 
implies that the WHO definition is more appropriate for 
clinical research purposes. In contrast the NCEP-ATP III 
definition is better suited for clinical practice because it only 
requires measurement of fasting blood glucose.[9]
Type 2 diabetes is becoming an epidemic world-wide[10] and 
the prevalence of diabetes in adults was estimated to be 4% 
in 1995 and it is predicted to rise to 5.4% by the year 2025. 
It is estimated to increase from 3.9% in 2010 to 4.3% in 
2030 in Nigeria.[11] Several studies have demonstrated 
that diabetes is associated with increased co-morbidities 
as found in metabolic syndrome and impaired functional 
health in the general adult population.[12,13] However, 
several other studies have demonstrated that intensive 
blood glucose control decreased the risk of complications 
in patients with type 2 diabetes.[14-16] The prevalence 
of metabolic syndrome is higher among diabetics than 
non-diabetics and is reported as 70-80% among Caucasian 
type 2 diabetics.[17,18] A study conducted in an Indian 
urban population gave a metabolic syndrome prevalence 
of 77.2% among type-2 diabetics.[19]
Not many studies have looked at the prevalence of 
metabolic syndrome in newly diagnosed type 2 diabetes 
in Nigeria as the bulk of studies have been on established 
type 2 diabetes. The purpose of this study is therefore to 
determine the prevalence of metabolic syndrome in newly 
diagnosed type 2 diabetes mellitus subjects.
Materials and Methods
One hundred and eighteen (118) newly diagnosed diabetic 
patients were recruited into the study from a private 
hospital-Hope Specialist Hospital, Nnewi. These were made 
up of those who on routine screening were found to have 
elevated blood glucose or were symptomatic of the disease 
and presented for treatment
Excluded from the study were those who had been previously 
diagnosed to have diabetes whether they have been 
receiving treatment or not, those <30 years of age, those 
with renal failure and ascites due to any cause.
Informed consent was obtained after fully explaining the 
procedure and objective of the study.
The first twenty five samples were lost as a result of 
prolonged power outage during storage prior to analysis 
leaving 93 for the study.
Seven measures representing the MetS were obtained, 
including fasting blood glucose (FBG), waist circumference, 
high-density lipoprotein cholesterol (HDL-C) and 
low-density lipoprotein cholesterol (LDL-C), triglycerides 
(TG), systolic blood pressure (SBP), and diastolic blood 
pressure (DBP), and additionally body mass index (BMI). 
At the baseline examination, blood samples were taken 
after minimum 6-hours overnight fast. Serum was separated 
on-site within 30 minutes of venipuncture, stored at 4°C, and 
analyzed within 24 hours of venipuncture. Determination 
of routine biochemical parameters was performed with 
standard techniques by using an autoanalyzer. Values for 
each person were calculated by Friedewald’s formula and 
LDL-C values >10.36 mmol/l were not taken into account.
Waist circumference was measured in the horizontal plane 
midway between the inferior margin of the ribs and the 
superior border of the iliac crest with the subject standing 
erect, arms by the sides but away from the trunk, abdomen, 
and breathing normally. A non-stretchable tape measure 
graduated in centimeters was used for the measurement. 
The plane of the tape was parallel to the floor and the tape 
was snug, but did not compress the skin. The measurements 
were recorded to the nearest 0.5 cm and taken at the end 
of normal inspiration.
BMI was calculated as the ratio of body weight to square 
of body height (kg/m2). Obesity was defined based on 
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BMI ≥30 kg/m2. Height measurement was done using 
a stadiometer and the subject stood barefoot with feet 
together, arms by the sides, and in a fully erect posture on 
the stadiometer foot-rest. The movable headboard was then 
placed on top of the subject’s head height is read off to the 
nearest 0.01 m. Weight was measured using a weighing scale 
and the subject wearing only light clothing and standing at 
the centre of the weighing scale and weight was read off to 
the nearest 0.5 kg.
Blood pressure was calculated as the average of three 
measurements taken under standardized conditions in a 
sitting position with a sphygmomanometer and hypertension 
was defined as ≥130 mmHg systolic blood pressure 
and ≥85 mmHg diastolic blood pressure according to 
NCEP-ATP III guideline.[5]
Diabetes mellitus was defined as a fasting blood glucose 
level ≥ 7 mmol/l.
MetS was defined in this study using the NCEP-ATP III[5] 
criteria, as any two or more of the following in the presence 
of diabetes. In other words, in this study involving type 2 DM 
they would only have two other risk factors to be deemed 
to suffer from the metabolic syndrome:
(a) WC men > 102 cm, women > 88 cm
(b) Raised triglyceride level ≥1.7 mmol/l
(c)  Reduced HDL-C < 1.03 mmol/l (male) or 1.29 mmol/l 
(female)
(d)  Raised blood pressure: systolic BP ≥ 130 mmHg or 
diastolic BP ≥ 85 mmHg or treatment of previously 
diagnosed hypertension.
Statistical analysis was carried out using SPSS version 13. 
Student’s t test was used for continuous variables, and a 
χ2 test was used for categorical variables. In the analyses 
a P value of < 0.05 was considered statistically significant
Result
During the study period 118 newly diagnosed adult type 2 
diabetes mellitus patients were seen. Of these 25 were removed 
from the study because the samples were lost as a result of 
prolonged power outage prior to analysis, leaving behind 93 
subjects consisting 47 males and 46 females who completed 
the study. Table 1 shows the mean (SD), and the range of 
age, WC, BMI, SBP, DBP, TC, LDL-C, HDL-C, TG. Out of 
the 93 newly diagnosed diabetic patients, 62 (66.7%) were 
found to have metabolic syndrome. Among these 62 patients 
that have MetS, 26 (41.9%) were males and 36 (58.1%) 
were females (P < 0.019), indicating that the disease is more 
common in females and that it is statistically significant. 
Table 2 shows characteristic of patients stratified by WC 
as a measure of obesity and gender for those with MetS. 
Table 3shows different components of metabolic syndrome in 
type 2 diabetic patients stratified by gender. Hypertension is 
the most common factor; it was found in 80.6% (75): 37 males 
and 38 females (P = 0.635) while dyslipidemia and obesity 
were found in 61.3% (57) and 51.6% (48) respectively. Of the 
study subjects 33 had hypertension prior to the diagnosis of 
diabetes (DM). A total of 20 males had hypertriglyceridemia 
against 19 females P = 0.903. Equal number of males and 
females (19 each) had low HDL P = 0.931. Figure 1 shows 
metabolic syndrome and associated number of risk factors.
Discussion
Metabolic syndrome has received a lot of attention recently 
because of its importance as a health problem and because 
of different definitions created by several organizations 
such as, WHO,[4] IDF,[7] and NCEP-ATP III.[5] Type 2 
diabetes mellitus, which accounts for 90% of all diabetes, 
has become one of the major causes of premature illness and 
death, mainly through the increased risk of cardiovascular 
disease (CVD)[20-24] and the addition of MetS further 
aggravates the situation.
We studied 93 newly diagnosed type-2 diabetes mellitus 
patients using NCEP-ATPIII[5] criteria. The study 
estimated a prevalence of 66.7%, which is very high. This 
is much higher than the rates obtained by Alebiosu and 
Odusan[25] who had a prevalence of 25.2%. Isezuo on the 
other hand had a prevalence of 54.3% in his study.[26] 
However it should be remembered that Alebiosu and 
Isezuo each had studied patients who had long standing 
diabetes unlike our study which studied newly diagnosed 
diabetes. Studies conducted in other parts of the world 
have prevalence rates of 70--80% among Caucasian type-2 
diabetics.[18,27-29] Mansour[29] reported one of the highest 
prevalence rates of MetS which was 86% (82.7% of males 
and 94.5% of females) among type 2 diabetic patients in 
Basrah. Differences in the prevalence of the MetS may 
be largely due to differences in lifestyles, age of the study 
Table 1: Characteristics of patients
Parameter Mean (SD) Range
Age (years) 55.27 (12.55) 24-84
SBP (mmHg) 153.52 (29.83) 100-230
DBP (mmHg) 94.23 (15.42) 60-140
TC (mmol/L) 5.17 (1.40) 2.0-11.12
HDL-C (mmol/L) 1.28 (0.48) 0.15-2.8
LDL-C (mmol/L) 2.06 (1.55) 0.1-9.40
TG (mmol/L) 1.75 (0.85) 0.5-5.0
WC men > 102 cm 101 (3.88) 85-108
Women > 88 cm 92 (6.77) 84-112
BMI kg/m2 30.30 (6.23) 17.84-49.12
SBP = Systolic blood pressure, DBP = Diastolic blood pressure, TC = Total 
cholesterol, HDL‑C = High density lipoprotein cholesterol, LDL‑C = 
Low density lipoprotein cholesterol, TG = Triglycerides, BMI = Body 
mass index, BMI = Body mass index, WC = Waist Circumference, 
SD = Standard deviation. Data are mean (SD) and values of minimum and 
maximum parameters
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population, and the non application of uniform diagnostic 
criteria.[30]
Different studies report quite varied effects of gender on the 
metabolic syndrome in different populations. We observed 
that metabolic syndrome was more common in females 
with type-2 diabetes mellitus compared to their male 
counterparts (P value < 0.019). This higher percentage 
had earlier been reported in Nigerian women with type-2 
diabetes mellitus.[31] In the USA, metabolic syndrome 
is more prevalent in white males than in females[28] but 
commoner in females among African-Americans and 
Mexican Americans. This sex difference in the prevalence 
of MetS is also found in Korea, Iran, India, Oman, Kinmen, 
and Japan where women were found to have a higher 
prevalence of the metabolic syndrome than men.[32-36] The 
gender difference in prevalence of MetS may be due to the 
higher prevalence of obesity in females than in males and 
also the relatively sedentary lifestyle of women, in this part 
of the world, due in part to cultural and social barriers. More 
importantly rapid urbanization and acquisition of western 
life style have resulted in decreased physical activity and 
increased calorie intake; two of the major contributors 
towards the development of diabetes and MetS.
Prevalence of the MetS tends to increase with age.[31,37] 
In this study we found that 72.5% were aged 50 years and 
above compared to 27.5% for those that were aged less than 
50 years (P < 0.014). The reason for this may be due to 
the fact that advancing age affects all levels of pathogenesis 
which likely explains why the prevalence of MetS rises 
with advancing age. For example aging is associated with 
evolution of insulin resistance, other hormonal alterations, 
and increases in visceral adipose tissue[38] all of which are 
important in the pathogenesis of the MetS.
When we categorized our patients with metabolic syndrome 
into three groups according to the number of metabolic risk 
factors present, we found that the majority of patients were 
those who had three risk factors in addition to diabetes mellitus 
followed by those having two plus diabetes and lastly those 
with four risk factors in addition to diabetes. This trend is not 
similar to that found in the Nigerian diabetic population[26] 
The explanation could well be that Isezuo studied people 
with longstanding diabetes mellitus who may had various 
treatments unlike in our study in which the subjects were 
newly diagnosed and had not had any type of treatment.
The prevalence of different risk factors in patients of both 
sexes with MetS was studied. As all the patients had diabetes 
mellitus, males and females were compared for the presence 
of obesity, hypertension, and dyslipidemia (low HDL-C and 
high triglycerides levels). We found hypertension (74.5%) 
to be the most prevalent risk factor in both sexes followed 
by dyslipidemia (60.8%) and obesity (45.1%). This differed 
from the study of Ogbera who found the most common 
component to be central obesity[39] but is in keeping with the 
findings of Alebiosu and Odusan[25] in Nigeria and Akbar[28] 
in Saudi MetS patients with type 2 diabetes mellitus, where 
they reported hypertension as the most common component 
of the syndrome. Ogbera[39] had studied long-standing type 2 
diabetes mellitus patients and this may have affected the 
Table 2: Characteristic of patients stratified by WC as a measure of obesity and gender
Parameter
WC male > 102 cm
female > 88 cm
Total Male with MetS % Total Female with MetS % P-value
47 20 42.6 46 36 60.9 0.000
MetS = Metabolic syndrome, WC = Waist circumference. Data are number (%).
Table 3: Different components of metabolic syndrome in type 2 diabetic patients stratified by gender
Parameter Total Male with MetS % Total Female with MetS % P-value
Hypertension 47 37 78.7 46 38 80.7 0.635
Dyslipidemia 47 29 61.7 46 28 60.9 0.934
Obesity 47 20 42.6 46 28 60.9 0.77
MetS = Metabolic syndrome;Data are number (%).
Figure 1: Number of risk factors and metabolic syndrome by sex
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result. The prevalence of 74.5% for hypertension when 
compared to national average may appear high but when 
looked at in the context of hypertension in type 2 diabetes 
mellitus given as 10%-55%[40] it is not so high. The role 
of hypertension in exacerbating cardiovascular diseases is 
well documented in epidemiologic literature. Its ability to 
result in morbidity and mortality make this high prevalence 
rate worrisome especially in a population that is battling 
with infectious diseases, like ours. There was no statistical 
difference in the prevalence of hypertension between 
the sexes P = 0.229 as well as those with dyslipidemia 
P = 0.572. However, we found obesity more prevalent in 
females P < 0.014. Further more of those with dyslipidemia 
high triglyceride occurred more commonly than those 
with low HDL-C. HDL-C dyslipidemia occurred equally 
in both males and females while high triglyceride occurred 
more commonly in males than in females which was not 
statistically significant P = 0.357
Caution must however be exercised in interpreting these data 
especially when extrapolating it for the general population 
because of the small sample size. This limited study showed 
a very high prevalence MetS in T2DM population. There is 
need to conduct a study involving a larger population that 
would help in drawing recommendations for the primary 
and secondary prevention of this syndrome.
Conclusion
This study showed a very high prevalence of metabolic 
syndrome in newly diagnosed type 2 diabetes in Nigeria. 
Females were more affected than males. Treatment should 
be centered not only on blood sugar control but also on the 
other components of the metabolic syndrome.
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